291 related articles for article (PubMed ID: 19101790)
1. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
2. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
3. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
4. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
6. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
Pietras RJ
Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
Morabito A; Sarmiento R; Bonginelli P; Gasparini G
Crit Rev Oncol Hematol; 2004 Feb; 49(2):91-107. PubMed ID: 15012971
[TBL] [Abstract][Full Text] [Related]
8. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
Johnston SR
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):889s-99s. PubMed ID: 15701883
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy: novel agents against cancer.
Tongyoo A
J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S311-23. PubMed ID: 21294432
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis for the treatment of sarcoma.
Balasubramanian L; Evens AM
Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapies in breast cancer.
Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis with integrative cancer therapies.
Yance DR; Sagar SM
Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of angiogenesis in cancer patients.
Verheul HM; Pinedo HM
Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
[TBL] [Abstract][Full Text] [Related]
14. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
15. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
Bao T; Smith BD; Karp JE
Clin Adv Hematol Oncol; 2005 Apr; 3(4):287-96, 302. PubMed ID: 16167001
[TBL] [Abstract][Full Text] [Related]
16. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
17. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
Albo D; Farrow B; Berger DH
Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
[TBL] [Abstract][Full Text] [Related]
18. Targeting growth factors and angiogenesis; using small molecules in malignancy.
Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
